生物技术公司阿尔尼拉姆制药（ALNY）今日盘中股价大涨13.23%，引起市场广泛关注。这一显著涨幅主要源于公司发布的最新季度财报超出市场预期。
根据公司公布的财报，截至6月30日的季度中，阿尔尼拉姆制药调整后每股亏损为51美分，远低于分析师平均预期的77美分亏损。公司营收同比增长17.3%，达到7.7369亿美元，同样超过了分析师预期的6.5678亿美元。这一业绩表现明显好于市场预期，推动了股价的大幅上涨。
值得注意的是，尽管公司仍然处于亏损状态，但亏损幅度的收窄和营收的增长显示出公司经营状况的持续改善。此外，华尔街分析师对公司保持乐观态度，平均评级为"买入"，12个月目标价中位数为353.00美元，较前一交易日收盘价高出约3.7%。这些因素共同推动了投资者的信心，促使股价在财报公布后出现大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.